Condition

Multiple Sclerosis, Chronic Progressive

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 19 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials19

Recruiting2

Common interventions25

Lead sponsors shown15

Clinical trials

19 shown

Impact of the Cionic Neural Sleeve on Mobility in Multiple SclerosisNCT05964829 · 2023-09-04

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair TherapyNCT05359653 · 2023-08-01

Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health CareNCT07280871 · 2026-12-01

NOT_YET_RECRUITING

Transient and Immediate Motor Effects of Exercise in Progressive Multiple SclerosisNCT05562414 · 2022-10-01

MUSCLE - Nordic Walking in MUltiple SCLErosisNCT05385731 · 2022-08-02

Exercise Effects in Multiple SclerosisNCT05496881 · 2022-06-15

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSNCT03799718 · 2019-03-13

Sensitivity of Motor Assessment in MS - a Prospective Cohort StudyNCT04993274 · 2019-02-20

Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS PatientsNCT04550650 · 2018-04-06

The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis PatientsNCT03424538 · 2018-02-05

Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)NCT02903537 · 2017-07-06

Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MSNCT03114293 · 2016-04-01

Intrathecal Rituximab in Progressive Multiple SclerosisNCT02545959 · 2015-11-30

Rotating Frame Relaxation Imaging in Patients With Multiple SclerosisNCT02403570 · 2015-02-01

China Betaferon Adherence, Coping and Nurse Support StudyNCT01436838 · 2012-03-01

Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)NCT01188811 · 2010-10-01

Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple SclerosisNCT00411723 · 2006-12-01

Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple SclerosisNCT00241254 · 2005-12-01

Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) PatientsNCT00220493 · 2003-06-01

Common interventions

Leading sponsors

Somogy Megyei Kaposi Mór Teaching Hospital 2 Artielle ImmunoTherapeutics 1 Bayer 1 Brainstorm-Cell Therapeutics 1 Centre Hospitalier de PAU 1 Cionic, Inc. 1 Friedemann Paul 1 Fundació Institut Germans Trias i Pujol 1 Klinik Valens 1 Leonardo A. Peyré-Tartaruga 1 Luxembourg Institute of Health 1 Sheba Medical Center 1 Turku University Hospital 1 Universitätsklinikum Hamburg-Eppendorf 1 University Hospital, Bordeaux 1

Trial status mix

COMPLETED8

UNKNOWN8

RECRUITING2

NOT_YET_RECRUITING1

Phase mix

NA7

PHASE14

PHASE24

PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.